Spero Therapeutics (SPRO) Balance Sheet: Assets & Liabilities

Spero Therapeutics (SPRO) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Spero Therapeutics reported total assets of $68.92M and total liabilities of $9.90M. Shareholders' equity was $59.02M, up 28.0% from $46.12M a year earlier. Total debt stood at $2.90M against $40.27M in cash and short-term investments, a net cash position of $37.37M. That puts debt-to-equity at 0.05, compared with 0.09 a year earlier.

Spero Therapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Spero Therapeutics, Inc. (SPRO) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Mar 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Current Assets
Cash and Cash Equivalents	40.27	52.89	76.33	109.11	112.58	112.58	85.21	29.73	34.08	87.29
Short-Term Investments	0.00	0.00	0.00	0.00	33.82	33.82	41.70	52.32	81.36	0.00
Cash & Short-Term Investments	40.27	52.89	76.33	109.11	146.40	146.40	126.91	82.05	115.44	87.29
Accounts Receivable	25.39	52.48	50.70	1.08	2.64	2.64	6.18	10.25	1.30	2.94
Inventory	0.00	0.00	0.00	-4.46	0.00	-	0.00	0.00	-8.78	-4.77
Other Current Assets	1.63	1.91	4.18	3.38	8.83	8.83	6.06	3.12	14.96	3.66
Total Current Assets	67.29	107.28	131.21	113.57	157.87	157.87	139.15	95.41	115.44	87.29
Non-Current Assets
Property, Plant & Equipment (Net)	1.48	3.11	4.16	5.49	7.56	7.56	8.78	7.15	2.89	1.16
Long-Term Investments	0.00	0.00	46.59	0.00	0.00	-	0.00	0.02	0.23	0.05
Other Non-Current Assets	0.15	0.15	0.44	5.74	5.64	5.64	5.52	3.52	10.44	4.98
Total Non-Current Assets	1.63	3.27	51.18	11.23	13.20	13.20	14.31	10.69	13.56	6.19
Total Assets	68.92	110.54	182.39	124.80	171.07	171.07	153.45	106.10	129.01	93.48
Current Liabilities
Accounts Payable	0.69	7.31	1.38	0.62	1.10	1.10	1.16	4.15	3.60	3.47
Short-Term Debt	1.96	1.75	1.72	1.69	1.36	-	0.95	0.93	0.00	0.00
Accrued Liabilities	5.58	17.72	6.56	8.97	-	14.35	12.24	-	-	-
Deferred Revenue	0.26	22.12	27.11	10.37	1.86	1.86	0.00	0.00	0.00	0.00
Other Current Liabilities	5.58	17.72	6.56	0.45	14.35	-	12.24	21.59	8.72	4.69
Total Current Liabilities	8.87	49.07	37.15	21.65	18.67	18.67	14.34	26.66	12.32	8.16
Non-Current Liabilities
Long-Term Debt	0.94	2.55	3.83	4.96	5.97	5.97	6.89	4.62	0.00	0.00
Other Non-Current Liabilities	0.09	0.58	0.09	0.10	49.35	48.55	0.18	0.25	0.83	0.37
Total Non-Current Liabilities	1.03	15.35	38.34	27.22	64.11	64.11	7.07	4.87	0.83	0.37
Total Liabilities	9.90	64.42	75.50	48.87	82.78	82.78	21.41	31.53	13.15	8.52
Stockholders' Equity
Common Stock	0.06	0.06	0.05	0.05	0.03	0.03	0.03	0.02	0.02	0.01
Retained Earnings	-451.07	-459.64	-391.07	-413.88	-367.46	-367.46	-277.71	-199.43	-138.50	-96.84
Accumulated Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.00	-0.01	0.02	-0.03	-0.64
Additional Paid-in Capital	510.03	505.71	497.91	489.76	455.72	455.72	409.72	273.97	254.01	181.43
Minority Interest	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.36	0.36
Shares Outstanding	56.41	54.59	53.00	52.46	-	32.39	-	-	-	-
Total Stockholders' Equity	59.02	46.12	106.89	75.93	88.29	88.29	132.04	74.57	115.86	84.96
Total Liabilities & Equity	68.92	110.54	182.39	124.80	171.07	171.07	153.45	106.10	129.01	93.48

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Spero Therapeutics Balance Sheet

How much debt does Spero Therapeutics have?

Spero Therapeutics had total debt of $2.90M as of Dec 31, 2025, against $40.27M in cash and short-term investments. Its debt-to-equity ratio was 0.05. Total debt was $4.30M a year earlier.

What are Spero Therapeutics's total assets?

Spero Therapeutics reported total assets of $68.92M as of Dec 31, 2025, down 37.7% from $110.54M a year earlier. Total liabilities were $9.90M.

What is Spero Therapeutics's shareholders' equity?

Spero Therapeutics's shareholders' equity was $59.02M as of Dec 31, 2025, or about $1.05 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition